- Home
- KIO vs ANAB Comparison
KIO vs ANAB Comparison
Compare KIO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- ANAB
- Stock Information
- Founded
- KIO 2011
- ANAB 2005
- Country
- KIO United States
- ANAB United States
- Employees
- KIO 2400
- ANAB N/A
- Industry
- KIO Investment Managers
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- KIO Finance
- ANAB Health Care
- Exchange
- KIO Nasdaq
- ANAB Nasdaq
- Market Cap
- KIO 522.7M
- ANAB 621.1M
- IPO Year
- KIO N/A
- ANAB 2017
- Fundamental
- Price
- KIO $12.46
- ANAB $20.22
- Analyst Decision
- KIO
- ANAB Buy
- Analyst Count
- KIO 0
- ANAB 10
- Target Price
- KIO N/A
- ANAB $48.00
- AVG Volume (30 Days)
- KIO 136.5K
- ANAB 459.5K
- Earning Date
- KIO 01-01-0001
- ANAB 08-06-2025
- Dividend Yield
- KIO 10.82%
- ANAB N/A
- EPS Growth
- KIO N/A
- ANAB N/A
- EPS
- KIO N/A
- ANAB N/A
- Revenue
- KIO N/A
- ANAB $123,164,000.00
- Revenue This Year
- KIO N/A
- ANAB N/A
- Revenue Next Year
- KIO N/A
- ANAB $24.39
- P/E Ratio
- KIO N/A
- ANAB N/A
- Revenue Growth
- KIO N/A
- ANAB 304.17
- 52 Week Low
- KIO $10.52
- ANAB $12.21
- 52 Week High
- KIO $13.59
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- KIO 42.25
- ANAB 34.66
- Support Level
- KIO $12.26
- ANAB $19.48
- Resistance Level
- KIO $12.70
- ANAB $20.35
- Average True Range (ATR)
- KIO 0.10
- ANAB 1.27
- MACD
- KIO -0.04
- ANAB -0.13
- Stochastic Oscillator
- KIO 34.21
- ANAB 18.49
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).